Patent intelligence · WO
WO 2022053188
NOUVELLES SÉQUENCES D'ADN ENCODANT DES ANTICORPS HUMAINS SCFV À ACTIVITÉ NEUTRALISANTE CONTRE LE SARS-CORONAVIRUS-2 ET LEURS UTILISATIONS
NOUVELLES SÉQUENCES D'ADN ENCODANT DES ANTICORPS HUMAINS SCFV À ACTIVITÉ NEUTRALISANTE CONTRE LE SARS-CORONAVIRUS-2 ET LEURS UTILISATIONS
Patent details — WO 2022053188
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Mar 17, 2022
- Expiration
- Mar 12, 2042
- Applicant
- ALFASIGMA SPA [IT]
- CPC classes
- A61K 39/ 00 A I, A61P 31/ 14 A I, A61P/3114
Quick answer
WO 2022053188 (NOUVELLES SÉQUENCES D'ADN ENCODANT DES ANTICORPS HUMAINS SCFV À ACTIVITÉ NEUTRALISANTE CONTRE LE SARS-CORONAVIRUS-2 ET LEURS UTILISATIONS) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Mar 17, 2022. Expires Mar 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFASIGMA SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I, A61P 31/ 14 A I, A61P/3114
More from ALFASIGMA SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 2022053188?
WO 2022053188 (NOUVELLES SÉQUENCES D'ADN ENCODANT DES ANTICORPS HUMAINS SCFV À ACTIVITÉ NEUTRALISANTE CONTRE LE SARS-CORONAVIRUS-2 ET LEURS UTILISATIONS) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Mar 17, 2022. Expires Mar 12, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2022053188?
ALFASIGMA SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2022053188 expire?
Our index shows an expiration date of Mar 12, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.